3 completed. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow FX-322: new trials by email Literature Review of FX-322 trials Research Report on FX-322
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FX-322 in Adults With Severe Sensorineural Hearing Loss FX-322, Placebo - Hearing Loss, Sensorineural, Noise Induced Hearing Loss | Phase 1 | Completed | Frequency Therapeutics | 31 | 2020-11-02 | 2022-02-01 |
| FX-322 in Adults With Age-Related Sensorineural Hearing Loss FX-322, placebo - Presbycusis, Hearing Loss, Sensorineural | Phase 1 | Completed | Frequency Therapeutics | 30 | 2020-09-17 | 2022-05-25 |
| FX-322 in Sensorineural Hearing Loss FX-322, Placebo - Sensorineural Hearing Loss | Phase 1 / Phase 2 | Completed | Frequency Therapeutics | 23 | 2018-07-03 | 2022-11-14 |
Hearing Loss, Sensorineural (3) · Hearing Loss, Noise-Induced (2) · Hearing Loss, Sudden (2) · Presbycusis (1)
United States (3)
Carl LeBel, PhD (2) · George Atiee, MD (1)